Elevated cytokine levels are known to downregulate expression and suppress activity of
cytochrome P450 enzymes (CYPs). Cytokine‐modulating therapeutic proteins (TPs) used in …

Drugs that modulate cytokine levels are often used for the treatment of cancer as well as
inflammatory or immunologic disorders. Pharmacokinetic drug-biologic interactions (DBIs) …

Disease-mediated therapeutic protein–drug interactions have recently gained attention from
regulatory agencies and pharmaceutical industries in the development of new biological …

Purpose For decades, inflammation has been considered a cause of pharmacokinetic
variability, mainly in relation to the inhibitory effect of pro-inflammatory cytokines on the …

Objective: To assess the impact of inflammation on cytochrome P450 (CYP) drug
metabolism in human subjects. Data Sources: A PubMed search was done from 1980 to July …

It is well‐recognized that therapeutic proteins (TPs) with pro‐inflammatory activities elevate
the pro‐inflammatory cytokines and result in cytokine‐drug interactions. In the current …

Aims Understanding drug–drug interactions (DDI) is a critical part of the drug development
process as polypharmacy has become commonplace in many therapeutic areas including …

Abstract Interleukin 6 (IL-6) plays a central role in the immunopathogenesis of rheumatoid
arthritis (RA) and tocilizumab [TCZ](an anti-IL-6 receptor antibody) has been shown to be …

Traditional in vitro human liver cell culture models lose key hepatic functions such as
metabolic activity during short-term culture. Advanced three-dimensional (3D) liver coculture …

Mosunetuzumab is a CD3/CD20 bispecific antibody. As an on‐target effect, transient
elevation of interleukin‐6 (IL‐6) occurs in early treatment cycles. A physiologically‐based …